Oct 28, 2025 at 12:05 AM#2
Your endo is right. Here's why:
Metformin and semaglutide work through completely different mechanisms that are genuinely complementary:
| Mechanism | Metformin | Semaglutide |
|---|---|---|
| Primary action | Reduces hepatic glucose output | Enhances insulin secretion (glucose-dependent) |
| Insulin sensitivity | Improves (muscle, liver) | Modest improvement |
| GI effects | Activates AMPK in gut, alters microbiome | Delays gastric emptying, reduces appetite |
| Weight effect | Neutral to modest loss | Significant loss |
| CV benefit | Yes (UKPDS) | Yes (SELECT) |
| Cancer risk reduction | Possible (observational data) | Under investigation |
| Cost | ~$4/month generic | $350-1350/month |
The SUSTAIN 6 trial (cardiovascular outcome trial for semaglutide) had 73% of participants on concomitant metformin. The STEP 2 trial (semaglutide for weight loss in T2DM) also allowed concomitant metformin. These trials demonstrated semaglutide's efficacy ON TOP of metformin, not instead of it.[1][2]
Metformin also has benefits that semaglutide doesn't replicate:
- AMPK activation (a fundamental metabolic sensor pathway)
- Mitochondrial complex I inhibition (unique mechanism)
- Potential longevity benefits (TAME trial is specifically studying this)
- Gut microbiome modulation (increases Akkermansia, short-chain fatty acid producers)
At $4/month with a 60+ year safety record, there's almost no reason to discontinue metformin unless you're having intolerable side effects. It costs nothing, adds complementary mechanisms, and may have benefits we don't even fully understand yet.
[1] Marso SP, Bain SC, Consoli A, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 2016;375(19):1834-1844.
[2] Davies M, et al. Lancet. 2021;397(10278):971-984.
[2] Davies M, et al. Lancet. 2021;397(10278):971-984.
15 10kim_atl_prep, sarah_TO, wendy_avl and 12 others
Reply Quote Save Share Report